Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 2/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421072 | 1.00 | CYP2A6 (0.54) | CYP2A6DPP4DPP8DPP9MAPT | |
| SCHEMBL514508 | 1.00 | CYP2A6 (0.54) | CYP2A6DPP4DPP8DPP9MAPT | |
| SCHEMBL514509 | 1.00 | CYP2A6 (0.54) | CYP2A6DPP4DPP8DPP9MAPT | |
| SCHEMBL2466886 | 1.00 | CYP2A6 (0.54) | CYP2A6DPP4DPP8DPP9MAPT | |
| Hydrochloric Acid SCHEMBL31036845 | 0.98 | CYP2A6 (0.53) | CYP2A6DPP4DPP8DPP9MAPT | |
| Hydrochloric Acid SCHEMBL4903646 | 0.98 | CYP2A6 (0.53) | CYP2A6DPP4DPP8DPP9MAPT | |
| Hydrochloric Acid SCHEMBL4903643 | 0.98 | CYP2A6 (0.53) | CYP2A6DPP4DPP8DPP9MAPT | |
| Trifluoroacetic Acid SCHEMBL6161392 | 0.92 | DPP4 (0.48) | CYP2A6DPP4DPP8DPP9MAPT | |
| SCHEMBL28905932 | 0.88 | CYP2A6 (0.54) | CYP2A6DPP4DPP8DPP9OPRD1 | |
| SCHEMBL14401103 | 0.88 | CYP2A6 (0.54) | CYP2A6DPP4DPP8DPP9OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567639-A | Polypeptide conjugates for intracellular delivery of binding peptides | 俄亥俄州国家创新基金会 | 2024-02-20 | — | — | CN | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4274838-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| CN-115135665-A | Cyclic proteins comprising cell penetrating peptides | 俄亥俄州国家创新基金会 | 2022-09-30 | — | — | CN | claimed |
| CN-114805487-A | Polypeptide compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022148974-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | claimed |
| WO-2022109058-A1 | NUCLEASES COMPRISING CELL PENETRATING PEPTIDE SEQUENCES | ENTRADA THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608452-A2 | PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Management Co., Ltd. (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2022148974-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| EP-4021473-A1 | STAPLED BETA-CATENIN LIGANDS | Ohio State Innovation Foundation (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-113912670-B | Angiotensin converting enzyme 2 inhibitor, application thereof and anti-coronavirus infection drug | 深圳市小分子新药创新中心有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3963109-A1 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-03-09 | — | — | EP | disclosed |
| EP-3956446-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-23 | — | — | EP | disclosed |
| EP-3952850-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022023379-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING A CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | CYP2A6 3815/4885DPP4 1515/4885DPP8 1159/4885 |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | CYP2A6 3144/4885DPP4 1094/4885DPP8 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.